Peter Clausen - 29 Jun 2026 Form 4 Insider Report for Nuo Therapeutics, Inc. (AURX)

Reporting relationship
CSO/COO
Issuer ticker
AURX
Reported as of
29 Jun 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
02 Jul 2026, 21:31:19 UTC
Prior SEC filing
04 Aug 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ David Jorden, attorney-in-fact

Key filing fact

Peter Clausen filed Form 4 for Nuo Therapeutics, Inc. (AURX) on 02 Jul 2026.

Key facts

  • This page summarizes Peter Clausen's Form 4 filing for Nuo Therapeutics, Inc. (AURX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 02 Jul 2026, 21:31.

Change

  • Previous filing in this sequence was filed on 04 Aug 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001605411 Primary reporting owner

CLAUSEN PETER

Relationship
CSO/COO
Address
C/O NUO THERAPEUTICS, INC., 8285 EL RIO, SUITE190, HOUSTON
Signature
/s/ David Jorden, attorney-in-fact
Signature date
02 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AURX transaction Derivative

Option to purchase common stock

Award

Transaction value
Shares
+65,000
Change %
Price
$0.000000*
Shares after
65,000
Date
29 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
65,000
Exercise price
$1.01
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .